Mölnlycke® Health Care announces US $15m investment in next-generation enzymatic therapeutics company MediWound Ltd

Contributed by: PR Newswire

Tags

MÖLNLYCKE-MediWound

More Like This

Mölnlycke® Health Care and Transdiagen announce research collaboration to drive innovation in wound care

Mölnlycke and Ondine join forces against HAIs

PR Newswire associated0

Large Independent Randomized Controlled Trial Validates MolecuLight's Transformative Impact on Wound Debridement, Showing Improved Outcomes and Lower Costs

PR Newswire associated0

MolecuLight Secures $27.5 Million From Hayfin, a Leading Healthcare Institutional Investor

PR Newswire associated0

MolecuLight Secures $11.7 Million in Financing to Accelerate Global Expansion

Mölnlycke® Health Care acquires P.G.F. Industry Solutions GmbH, the manufacturer of Granudacyn®, a range of solutions for wound cleansing and moisturising

DEBx Medical Secures Expanded Investment from TVM Capital Healthcare

PR Newswire associated0

MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep Sternal Wound Infections in Taiwan Study; Signals Expansion into Surgical Applications